A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
Condition(s):T-cell Acute Lymphoblastic Leukemia; T-lymphoblastic LymphomaLast Updated:November 29, 2022Withdrawn
Hide Studies Not Open or Pending
Condition(s):T-cell Acute Lymphoblastic Leukemia; T-lymphoblastic LymphomaLast Updated:November 29, 2022Withdrawn
Condition(s):Advanced Solid TumorLast Updated:August 3, 2018Unknown status
Condition(s):Refractory or Relapsed Multiple MyelomaLast Updated:October 12, 2020Unknown status
Condition(s):Multiple Myeloma; Immune System DiseasesLast Updated:August 15, 2023Recruiting
Condition(s):Primary Hepatocellular CarcinomaLast Updated:September 18, 2018Unknown status
Condition(s):T-cell Leukemia; T-cell LymphomaLast Updated:June 28, 2021Unknown status
Condition(s):Diffuse Large B-cell LymphomaLast Updated:November 7, 2023Recruiting
Condition(s):Nonsmall Cell Lung Cancer; Solid Tumor, AdultLast Updated:February 14, 2023Recruiting
Condition(s):Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin Lymphoma, B-cell; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma; Lymphoma, Follicular; MCLLast Updated:January 23, 2024Not yet recruiting
Condition(s):Central Nervous System Tumor, Pediatric; Glioma; Ependymoma; Medulloblastoma; Germ Cell Tumor; Atypical Teratoid/Rhabdoid Tumor; Primitive Neuroectodermal Tumor; Choroid Plexus Carcinoma; PineoblastomaLast Updated:October 27, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.